Participations

Immutep

http://www.immutep.com/

Immutep est une société de biotechnologie active sur le développement de molécules biologiques (protéines) en thérapeutique humaine. Les indications prioritaires de la société sont centrées sur l’oncologie. Plusieurs essais cliniques ont été complétés ou sont en cours, et ont permis de valider la preuve de principe de l’approche d’Immutep.


Secteur :	biothérapeutiques
Localisation :	Paris, France

Fonds :	Innoven FCPI 2001, 2002. FCPI Poste Innovation 1, 2, 3

Contact:	Thomas Balland

Actualités en relation avec :

Immutep

10/01/2010

2010-01-06 Immutep And GlaxoSmithKline Signe Licence Agreement For IMP731 A Novel Therapeutic Antibody For The Treatment Of Autoimmune Diseases

2011-01-06_immutep-and-glaxosmithkline-signe-licence-agreement-for-imp731-a-novel-therapeutic-antibody-for-the-treatment-of-autoimmune-diseases

05/01/2010

2010-01-05 Immutep and GlaxoSmithKline sign licence agreement for IMP731, a novel therapeutic antibody for the treatment of autoimmune diseases

immutep-2010-01-06

05/01/2009

2009-01-05 Immutep Announces Positive Interim Results In Phase I-II Chemoimmunotherapy Trial In Breast Cancer

Immutep Announces Positive Interim Results In Phase I-II Chemoimmunotherapy Trial In Breast Cancer

25/09/2006

2006-09-25 Immutep Announces That ImmuFact® IMP321 Has Entered a Phase I Therapeutic Vaccine Trial in Melanoma

Immutep Announces That ImmuFact® IMP321 Has Entered a Phase I Therapeutic Vaccine Trial in Melanoma

03/08/2006

2006-08-03 Immutep Announces That ImmuFact® IMP321 Has Entered A Phase I Chemoimmunotherapy Trial In Breast Cancer

Immutep Announces That ImmuFact® IMP321 Has Entered A Phase I Chemoimmunotherapy Trial In Breast Cancer

30/05/2006

2006-05-30 Immutep announces that Immufact® IMP321 has successfully completed phase I studies

IMMUTEP ANNOUNCES THAT IMMUFACT® IMP321 HAS SUCCESSFULLY COMPLETED PHASE I STUDIES

22/11/2005

2005-11-22 Immutep initiates phase I clinical trial in renal cell cancer

IMMUTEP INITIATES PHASE I CLINICAL TRIAL IN RENAL CELL CANCER

25/04/2005

2005-04-25 Immutep enters Phase I and II clinical trials with Immufact®, a novel immunostimulatory factor

IMMUTEP ENTERS PHASE I/II CLINICAL TRIALS WITH IMMUFACT®, A NOVEL IMMUNOSTIMULATORY FACTOR

10/01/2005

2005-01-10 Immutep closes second funding to enter clinic

IMMUTEP CLOSES SECOND FUNDING TO ENTER CLINIC

15/04/2004

2005-01-10 Immutep closes funding to develop novel therapeutic vaccines

IMMUTEP CLOSES FUNDING TO DEVELOP NOVEL THERAPEUTIC VACCINES

Innoven Partenaires est une société de gestion en capital investissement spécialisée dans la gestion de FCPI. Notre approche est de faire progresser les actifs confiés par tous les moyens qu’offrent le capital investissement. Pas encore inscrit ? Vous trouverez toutes les informations de souscription à nos FCPI sur notre page souscripteurs.

© Copyright 2012 - Innoven Partners